A Phase 1 Study of XmAb5574 to Evaluate the Safety, Tolerability, and Pharmacokinetics in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Phase of Trial: Phase I/II
Latest Information Update: 25 Mar 2015
At a glance
- Drugs MOR 208 (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions; First in man
- Sponsors Xencor
- 25 Mar 2015 According to a MorphoSys media release, results from this trial were presented at the Annual Meeting of the American Society of Hematology.
- 07 Dec 2014 Final results published in a MorphoSys Media Release.
- 07 Oct 2013 Status changed from active, no longer recruiting to completed, according to a MorphoSys media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History